Product nameAnti-Factor B antibody
See all Factor B primary antibodies
DescriptionRabbit polyclonal to Factor B
Specificityab72658 detects a fragment from activated Factor B; the Bb fragment, resulting from cleavage adjacent to Lys260.
Tested applicationsSuitable for: WB, ELISAmore details
Species reactivityReacts with: Human
Predicted to work with: Mouse, Sheep, Chimpanzee, Gorilla, Orangutan
- Extracts from K562 cells, treated with etoposide (25uM, 1hour).
Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
Storage bufferpH: 7.40
Preservative: 0.02% Sodium azide
Constituents: 50% Glycerol, 0.87% Sodium chloride, PBS
Without Mg2+ and Ca2+
Concentration information loading...
PurityImmunogen affinity purified
Our Abpromise guarantee covers the use of ab72658 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/500 - 1/1000. Detects a band of approximately 54 kDa (predicted molecular weight: 61 kDa).|
FunctionFactor B which is part of the alternate pathway of the complement system is cleaved by factor D into 2 fragments: Ba and Bb. Bb, a serine protease, then combines with complement factor 3b to generate the C3 or C5 convertase. It has also been implicated in proliferation and differentiation of preactivated B-lymphocytes, rapid spreading of peripheral blood monocytes, stimulation of lymphocyte blastogenesis and lysis of erythrocytes. Ba inhibits the proliferation of preactivated B-lymphocytes.
Involvement in diseaseDefects in CFB are a cause of susceptibility to hemolytic uremic syndrome atypical type 4 (AHUS4) [MIM:612924]. An atypical form of hemolytic uremic syndrome. It is a complex genetic disease characterized by microangiopathic hemolytic anemia, thrombocytopenia, renal failure and absence of episodes of enterocolitis and diarrhea. In contrast to typical hemolytic uremic syndrome, atypical forms have a poorer prognosis, with higher death rates and frequent progression to end-stage renal disease. Note=Susceptibility to the development of atypical hemolytic uremic syndrome can be conferred by mutations in various components of or regulatory factors in the complement cascade system. Other genes may play a role in modifying the phenotype.
Sequence similaritiesBelongs to the peptidase S1 family.
Contains 1 peptidase S1 domain.
Contains 3 Sushi (CCP/SCR) domains.
Contains 1 VWFA domain.
- Information by UniProt
- AHUS4 antibody
- B factor properdin antibody
- BF antibody
All lanes : Anti-Factor B antibody (ab72658) at 1/200 dilution
Lane 1 : Extracts from K562 cells, treated with etoposide (25uM, 1hour)
Lane 2 : Extracts from K562 cells, treated with etoposide (25uM, 1hour) with Cl-peptide at 5 µg
Lysates/proteins at 5 µg per lane.
Predicted band size: 61 kDa
Observed band size: 54 and 86 kDa why is the actual band size different from the predicted?
Additional bands at: 40 kDa (possible non-specific binding), 75 kDa. We are unsure as to the identity of these extra bands.
ab72658 has not yet been referenced specifically in any publications.